This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Trout, H. Articles by Bergmann, J.-F. Search for Related Content PubMed PubMed Citation Articles by Trout, H. Articles by Bergmann, J.-F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2004, p. 538-545, Vol. 48, No. 2
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.2.538-545.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Enhanced Saquinavir Exposure in Human Immunodeficiency Virus Type 1-Infected Patients with Diarrhea and/or Wasting Syndrome

Laboratoire de Toxicologie et Pharmacologie Clinique, Service de Pharmacie,¹ Unité de Recherches Thérapeutiques, Hôpital Lariboisière,³ INSERM E0357, Département d'Epidémiologie, Biostatistique et Recherche Clinique, Hôpital Bichat-Claude Bernard,² Laboratoire de Biochimie A, Hôpital Saint-Antoine,⁵ Service de Coprologie Fonctionnelle, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris,⁶ Service des Maladies Infectieuses, Hôpital Paul Brousse, AP-HP, Villejuif, France⁴

Received 21 March 2003/ Returned for modification 30 May 2003/ Accepted 30 October 2003

The protease inhibitor saquinavir was administered to 100 human immunodeficiency virus type 1 (HIV-1)-infected patients as a single 600-mg oral dose (hard gelatin capsules) with a standard breakfast, including 200 ml of grapefruit juice, during an open-label trial to assess whether diarrhea and/or wasting syndrome has consequences on its pharmacokinetics. Three groups of patients were enrolled: group 1, asymptomatic patients (n = 30); group 2, AIDS symptomatic patients without body weight loss or diarrhea (n = 37); and group 3, AIDS symptomatic patients with severe body weight loss and/or diarrhea (n = 33). Clinical and biological data (covariates) were collected. A population approach was performed with three blood samples per patient to estimate the mean population pharmacokinetic parameters (clearance [CL]/oral bioavailability [F], V/F, k_a, and lag time) and the derived ones (k_el, C_max, T_max, and area under the curve [AUC]). The relationships between groups, exposure (i.e., estimated individual post hoc AUCs), and covariates were explored by using multiple linear regressions. A significant increase in median AUCs (165, 349, and 705 ng · h · ml^-1 for groups 1, 2, and 3, respectively [P < 0.0001]) was observed. The enhancement in saquinavir exposure could be due to the destruction of the transporters in enterocytes and/or to the enlargement of their tight junctions, allowing a paracellular crossing of saquinavir as the illness spreads. Because of grapefruit juice intake by every patient, no implication of CYP3A4 could be assessed. These results strongly suggest that, despite its low intrinsic oral bioavailability, saquinavir can be considered as a relevant treatment for HIV-1-infected patients with diarrhea and/or wasting syndrome. This must be evaluated in a long-term period.

This article has been cited by other articles:

• Dickinson, L., Boffito, M., Back, D. J., Khoo, S. H., Pozniak, A. L., Mugyenyi, P., Merry, C., Autar, R. S., Burger, D. M., Aarons, L. J. (2008). Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. J Antimicrob Chemother 0: dkn399v1-12 [Abstract] [Full Text]